Johnson & Johnson Innovation – JLABS

Johnson & Johnson Innovation – JLABS
Name	Johnson & Johnson Innovation – JLABS
Type	Life science incubator
Industry	Biotechnology, Pharmaceutical industry, Medical device
Founded	0 2012
Founder	Johnson & Johnson
Headquarters	South San Francisco, California, United States
Area served	Global
Key people	Melinda Richter (Global Head)
Website	https://jlabs.jnjinnovation.com/

Johnson & Johnson Innovation – JLABS. It is a global network of life science incubators established by the multinational corporation Johnson & Johnson to foster early-stage innovation. Operating as a capital-efficient, no-strings-attached model, JLABS provides emerging companies with state-of-the-art laboratory facilities, expert mentorship, and a collaborative ecosystem. Its mission is to accelerate the development of groundbreaking healthcare solutions across pharmaceuticals, medical technology, and consumer health.

Overview

Johnson & Johnson Innovation – JLABS functions as a premier open innovation ecosystem designed to empower entrepreneurs and scientists. The initiative is a core component of the broader Johnson & Johnson Innovation framework, which includes venture capital through JJDC, Inc. and strategic deal-making. By offering shared infrastructure and resources, JLABS lowers the traditional barriers to entry in the highly regulated and capital-intensive life sciences sector. This model allows innovators to focus their resources on core research and development activities aimed at addressing unmet medical needs.

History and development

JLABS was launched in 2012 with its inaugural site at the California Institute for Quantitative Biosciences (QB3) on the Mission Bay campus of the University of California, San Francisco. The concept was developed to create a more efficient and accessible pathway for translating academic and entrepreneurial science into viable companies. Under the leadership of Global Head Melinda Richter, the network has expanded significantly from its first location. This growth reflects a strategic response to the globalization of the biotechnology industry and the desire to tap into regional innovation hubs worldwide.

Locations and facilities

The JLABS network spans key life science clusters across North America, Europe, and Asia. Major locations include flagship sites in South San Francisco, California, Boston, New York City, Houston, Toronto, London, Shanghai, and Tokyo. Each facility is equipped with modern, modular laboratory suites, core instrumentation, and shared office spaces. For instance, JLABS @ Shanghai is situated in the Zhangjiang Hi-Tech Park, while JLABS @ Washington, D.C. is located on the campus of the Children's National Hospital. This geographic diversity provides portfolio companies with localized support and connectivity to regional investors and partners.

Incubation model and services

The JLABS model is distinguished by its "no-strings-attached" approach, meaning resident companies retain full intellectual property and equity independence. Key services include access to fully equipped wet and dry labs, specialized equipment like flow cytometers and high-throughput screening robotics, and business development support. Residents benefit from educational programming, networking events with venture capital firms like Andreessen Horowitz, and mentorship from seasoned industry experts from Johnson & Johnson and the broader community. This comprehensive support system is designed to de-risk the early stages of company formation.

Notable companies and successes

The JLABS portfolio has nurtured numerous companies that have achieved significant milestones, including lucrative acquisitions and successful initial public offerings. Notable alumni include Akouos, a gene therapy company for hearing loss acquired by Eli Lilly and Company, and Gossamer Bio, which completed a major IPO. Other successes include Viela Bio, focused on autoimmune diseases and acquired by Horizon Therapeutics, and Xilio Therapeutics, a cancer immunotherapy firm. These outcomes demonstrate the incubator's role in catalyzing the growth of high-potential startups.

Partnerships and collaborations

JLABS establishes strategic partnerships with academic institutions, research hospitals, and government agencies to source innovation. Key collaborators include the University of Texas system for JLABS @ TMC, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for the London site, and the Tokyo Metropolitan Government. These partnerships often involve creating tailored innovation challenges and providing regulatory guidance. Collaboration with organizations like the Bill & Melinda Gates Foundation has also supported global health initiatives within the incubator.

Impact and recognition

Since its inception, JLABS has supported over 800 companies, which have collectively raised more than $30 billion in follow-on financing. Its impact is measured by the acceleration of therapeutic and technological advancements reaching patients, contributing to the broader biopharmaceutical innovation landscape. The model has received industry recognition, including awards from the Global Federation of Competitiveness Councils. By democratizing access to critical resources, JLABS has become a influential blueprint for corporate-backed open innovation in healthcare.

Category:Johnson & Johnson Category:Business incubators Category:Biotechnology organizations Category:Organizations established in 2012